ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) for AMGEN
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
- Issues relating to the 340B Drug Pricing Program - FDA Reauthorization Act (H.R. 2430/S. 934) - American Health Care Act (H.R. 1628) and Better Care Reconciliation Act - Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA VI) - Issues related to biosimilars, generally - Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771) - Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| ISRAEL S KLEIN | — |
| VINCENT A. ROBERTI, SR. | — |
Taxation/Internal Revenue Code TAX
- International corporate tax reform; Puerto Rico tax incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| ISRAEL S KLEIN | — |
| VINCENT A. ROBERTI, SR. | — |
Medicare/Medicaid MMM
- Issues related to Medicare Part B (Average Sales Price) and Part D (rebates)
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| ISRAEL S KLEIN | — |
| VINCENT A. ROBERTI, SR. | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.